Dr. Lal Path Labs has announced the acquisition of a 100% stake in Shahbazkers Diagnostic Centre Private Limited (SDCPL), making it a wholly owned subsidiary. This strategic move aims to strengthen the company’s market presence.
The board of directors of Dr. Lal Path Labs, in their meeting held on April 30, 2026, approved several key decisions, including the audited financial results for the quarter and financial year ended March 31, 2026. The results, both standalone and consolidated, have been reviewed and approved by the board.
Additionally, the board has recommended a final dividend of ₹4 per equity share, representing a 40% dividend on a face value of ₹10 per share, for the financial year ended March 31, 2026. This recommendation is subject to the approval of the company’s members at the upcoming Annual General Meeting (AGM). The record date for the payment of the final dividend is set for June 26, 2026, and it will be credited within 30 days of member approval.
The acquisition of SDCPL is expected to enhance Dr. Lal Path Labs’ diagnostic capabilities and expand its footprint in the healthcare sector. The disclosure related to this acquisition, as required under Regulation 30 of the Listing Regulations, is enclosed with the filing.
Disclaimer: This article is based on a regulatory filing submitted to the National Stock Exchange of India (NSE).